https://pharmdguru.com/6-drug-induced-liver-disorders/ write notes for topic of drug-induced-liver-disorders therapeutics 3 it should include intro definition etiology pathophysiology in flowchart clinical features diagnosis treatment goals non pharmac treatment pharmacological treatment including drug short intro class short moa in flowchart drug interaction adr dose indication contraindication and summary chart for pharmacological treatment https://pharmdguru.com/6-drug-induced-liver-disorders/ use this link too with extra source too
https://pharmdguru.com/6-drug-induced-liver-disorders/
drug induced liver injury DILI pharmacological treatment N-acetylcysteine ursodeoxycholic acid corticosteroids dose mechanism
"drug-induced liver injury" AND management
~/DILI-notes/Drug_Induced_Liver_Disorders_Therapeutics3.md
# DRUG-INDUCED LIVER DISORDERS (DILI)
### Therapeutics 3 - Comprehensive Study Notes
---
## 1. INTRODUCTION
The liver is the primary site of drug metabolism, making it uniquely vulnerable to toxic injury from drugs and other xenobiotics. Drug-Induced Liver Injury (DILI) is one of the most serious adverse drug reactions and remains a leading cause of acute liver failure (ALF), post-marketing drug withdrawals, and drug development failures.
- DILI accounts for **~50% of all cases of acute liver failure (ALF) in the United States**
- Acetaminophen (paracetamol) is the **single most common** causative agent
- Over **1,000 drugs, herbal medicines, and dietary supplements** have been implicated (NIH LiverTox database)
- True incidence may be **10x higher** than reported due to underdiagnosis and incomplete reporting
---
## 2. DEFINITION
> **Drug-Induced Liver Injury (DILI)** is liver damage caused by drugs, herbal products, dietary supplements, or chemicals, defined by threshold elevations in liver chemistry tests, when other etiologies have been excluded.
### Biochemical Threshold Definition (Table 136-1, Goldman-Cecil):
| Marker | Threshold |
|---|---|
| ALT or AST | > 3× ULN (Upper Limit of Normal) |
| ALP | > 2× ULN |
| Total Bilirubin | > 2× ULN |
### Pattern Classification (R Ratio):
> **R Ratio = (ALT/ULN) ÷ (ALP/ULN)**
| R Value | Pattern |
|---|---|
| R > 5 | Hepatocellular injury |
| R < 2 | Cholestatic injury |
| R 2–5 | Mixed injury |
---
## 3. ETIOLOGY (Common Hepatotoxic Agents)
| Drug Class | Examples |
|---|---|
| **Analgesics / Antipyretics** | Acetaminophen (paracetamol), NSAIDs (diclofenac, sulindac) |
| **Antibiotics** | Amoxicillin-clavulanate, isoniazid, rifampicin, tetracyclines, nitrofurantoin |
| **Anticonvulsants** | Phenytoin, carbamazepine, valproic acid |
| **Antifungals** | Ketoconazole, fluconazole, itraconazole |
| **Antivirals** | Highly active antiretroviral therapy (HAART), nevirapine |
| **Cardiovascular Drugs** | Amiodarone, statins, methyldopa, hydralazine |
| **Antitubercular Drugs** | INH + Rifampicin + Pyrazinamide (combination regimen) |
| **Immunosuppressants** | Methotrexate, azathioprine, checkpoint inhibitors |
| **Herbal / Supplements** | Kava, pyrrolizidine alkaloids, green tea extract, black cohosh |
| **Antidiabetics** | Troglitazone (withdrawn), pioglitazone (rare) |
---
## 4. PATHOPHYSIOLOGY (Flowchart)
```
DRUG EXPOSURE
│
▼
┌─────────────────────────────────────────────────────────┐
│ HEPATIC DRUG METABOLISM │
│ (CYP450 enzymes in hepatocytes) │
└────────────────────┬────────────────────────────────────┘
│
┌───────────┴────────────┐
│ │
▼ ▼
DIRECT (Intrinsic) IDIOSYNCRATIC
HEPATOTOXICITY HEPATOTOXICITY
│ │
Dose-dependent Not dose-dependent
Predictable Unpredictable, rare
(e.g., Paracetamol) (<1:1000 patients)
│ │
▼ ▼
┌─────────────────┐ ┌───────────────────────┐
│ TOXIC METABOLITE│ │ IMMUNE-MEDIATED │
│ FORMATION (NAPQI│ │ • Hapten formation │
│ from paracetamol│ │ • Reactive metabolites│
│ via CYP2E1) │ │ • HLA-restricted T- │
└────────┬────────┘ │ cell activation │
│ └──────────┬────────────┘
▼ │
GLUTATHIONE DEPLETION ▼
│ INNATE & ADAPTIVE IMMUNE
▼ ACTIVATION
COVALENT BINDING TO │
HEPATIC PROTEINS ▼
│ CYTOKINE STORM (TNF-α, IL-6)
▼ │
MITOCHONDRIAL DYSFUNCTION ▼
│ HEPATOCYTE APOPTOSIS/NECROSIS
▼
OXIDATIVE STRESS / ROS
│
▼
HEPATOCYTE NECROSIS / APOPTOSIS
│
▼
┌────────────────────────────────────────────┐
│ PATTERNS OF LIVER INJURY │
│ Hepatocellular | Cholestatic | Mixed │
│ Steatosis | Fibrosis | Vascular injury │
└────────────────────────────────────────────┘
```
### Key Mechanisms:
1. **Intrinsic (Direct) Hepatotoxicity:**
- Dose-dependent, predictable
- Drug or toxic metabolite directly damages hepatocytes
- Example: Paracetamol → NAPQI (via CYP2E1/CYP3A4) → depletes glutathione → covalent binding to proteins → mitochondrial dysfunction → zone 3 centrilobular necrosis
2. **Idiosyncratic Hepatotoxicity:**
- Unpredictable, not dose-dependent
- Two subtypes:
- *Metabolic idiosyncrasy*: Unusual metabolism producing toxic intermediate
- *Immune idiosyncrasy*: Drug/metabolite acts as hapten → triggers adaptive immune response → T-cell mediated hepatocyte destruction
- Example: Isoniazid, halothane, diclofenac
3. **Indirect Hepatotoxicity:**
- Results from the drug's primary pharmacological effect (not direct toxicity)
- Increasingly recognized with newer immunotherapy agents (checkpoint inhibitors)
- Example: Anti-PD-1 antibodies → immune activation → liver inflammation
---
## 5. CLINICAL FEATURES
### 5.1 General Symptoms
| Symptom | Description |
|---|---|
| Fatigue / Malaise | Most common early symptom |
| Nausea & Vomiting | Common, especially with hepatocellular injury |
| Anorexia | Loss of appetite |
| Fever | Especially in hypersensitivity/immune reactions |
| Right upper quadrant pain | Hepatic inflammation |
### 5.2 Hepatic-Specific Symptoms
| Symptom | Pattern Suggests |
|---|---|
| Jaundice (icterus) | Elevated bilirubin; indicates significant injury |
| Dark urine (bilirubinuria) | Cholestatic or hepatocellular injury |
| Pale/acholic stools | Cholestatic injury (bile flow obstruction) |
| Pruritus (itching) | Cholestatic injury - bile salt accumulation in skin |
| Hepatomegaly | Hepatic inflammation / steatosis |
### 5.3 Severe / Advanced Features
| Feature | Significance |
|---|---|
| Coagulopathy (prolonged PT/INR) | Hepatic synthetic dysfunction |
| Hepatic encephalopathy | ALF; asterixis, confusion, coma |
| Ascites | Portal hypertension / hypoalbuminemia |
| Peripheral edema | Hypoalbuminemia |
| Splenomegaly | Portal hypertension |
| GI bleeding | Variceal hemorrhage in advanced disease |
### 5.4 Hypersensitivity Features
- Skin rash (maculopapular, urticarial)
- Eosinophilia (> 5% of WBC)
- Fever + lymphadenopathy
- DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)
---
## 6. DIAGNOSIS
### 6.1 Clinical Approach
DILI is a **diagnosis of exclusion** - all other causes of liver disease must be ruled out first.
**Key Principle:** Establish temporal relationship between drug exposure and onset of liver injury.
### 6.2 History (MUST obtain):
- Complete medication history (including OTC, herbals, supplements)
- Start and stop dates of all drugs
- Dose and duration
- Prior episodes of drug-induced liver injury
- Alcohol use history
### 6.3 Biochemical Tests
| Test | Hepatocellular | Cholestatic | Mixed |
|---|---|---|---|
| ALT / AST | Markedly elevated (>3× ULN) | Mildly elevated | Elevated |
| ALP | Mildly elevated | Markedly elevated (>2× ULN) | Elevated |
| GGT | Mild elevation | Markedly elevated | Elevated |
| Total Bilirubin | Elevated | Elevated (conjugated) | Elevated |
| PT/INR | Prolonged in severe cases | Usually normal | Variable |
| Albumin | Low in chronic/severe cases | Usually normal | Variable |
### 6.4 Exclusion Tests (First-Line)
- Hepatitis A IgM, Hepatitis B surface antigen + HBcAb IgM, anti-HCV + HCV RNA
- ANA, anti-smooth muscle antibody (ASMA), anti-LKM antibodies (autoimmune hepatitis)
- Abdominal ultrasound (doppler) / CT scan / MRI with contrast
- Ceruloplasmin + serum copper (Wilson's disease in younger patients)
- Ferritin + iron studies (hemochromatosis)
### 6.5 Second-Line Tests
- Anti-HEV, CMV, EBV, HSV serologies
- Liver biopsy (if diagnosis unclear, to exclude competing causes, or grade severity)
### 6.6 RUCAM Causality Assessment Scale
The **Roussel Uclaf Causality Assessment Method (RUCAM)** is the most widely used scoring system:
| Score | Probability |
|---|---|
| > 8 | Highly probable |
| 6–8 | Probable |
| 3–5 | Possible |
| 1–2 | Unlikely |
| ≤ 0 | Excluded |
**Parameters scored:** Time to onset, course after stopping drug, risk factors, concomitant drugs, non-drug causes excluded, prior information on drug, rechallenge result.
### 6.7 Hy's Law
> **Hy's Law:** ALT > 3× ULN + Total bilirubin > 2× ULN (with no cholestasis) → **~10% mortality risk**
---
## 7. TREATMENT GOALS
| Goal | Description |
|---|---|
| 1. Stop hepatic injury | Identify and discontinue offending drug immediately |
| 2. Prevent progression to ALF | Monitor LFTs, coagulation, and clinical status |
| 3. Provide symptomatic relief | Treat nausea, pruritus, encephalopathy |
| 4. Prevent complications | Manage coagulopathy, ascites, HE |
| 5. Prevent recurrence | Avoid re-exposure to offending drug |
| 6. Liver transplantation | If ALF fails to resolve with medical therapy |
---
## 8. NON-PHARMACOLOGICAL TREATMENT
| Intervention | Details |
|---|---|
| **Immediate discontinuation of offending drug** | MOST IMPORTANT step; majority recover spontaneously |
| **GI decontamination** | In acute toxic ingestion: gastric lavage or activated charcoal within 1–2 hours of ingestion (especially paracetamol overdose) |
| **Nutritional support** | High calorie, high protein diet (unless HE); avoid hepatotoxic foods |
| **Alcohol abstinence** | Complete cessation of alcohol |
| **Hydration** | IV fluids for nausea/vomiting, hypoglycemia |
| **Rest** | Physical rest during acute phase |
| **Avoid other hepatotoxic drugs** | NSAIDs, alcohol, herbal products |
| **Hospitalization criteria** | High bilirubin, rising INR, signs of encephalopathy, Hy's law pattern |
| **Liver transplant evaluation** | Transfer to transplant center for ALF unresponsive to medical therapy |
| **Patient education** | Medication adherence, self-reporting of symptoms, avoid self-medication |
| **Drug rechallenge avoidance** | Do NOT rechallenge with suspected offending drug |
---
## 9. PHARMACOLOGICAL TREATMENT
### 9.1 Overview of Drug Classes Used in DILI
| Drug | Class | Indication in DILI |
|---|---|---|
| N-Acetylcysteine (NAC) | Antidote / Glutathione precursor | Paracetamol toxicity; severe non-paracetamol DILI/ALF |
| Ursodeoxycholic Acid (UDCA) | Cytoprotective bile acid | Cholestatic DILI, pruritus |
| Cholestyramine | Bile acid sequestrant | Pruritus in cholestatic DILI; leflunomide toxicity |
| Corticosteroids | Anti-inflammatory/Immunosuppressant | Hypersensitivity DILI, DRESS, autoimmune features, checkpoint inhibitor hepatitis |
| L-Carnitine | Metabolic cofactor | Valproic acid hepatotoxicity with hyperammonemia |
| Diphenhydramine / Hydroxyzine | Antihistamine | Symptomatic pruritus |
| Lactulose | Ammonia reducing agent | Hepatic encephalopathy complicating ALF |
| Rifaximin | Non-absorbable antibiotic | Hepatic encephalopathy |
---
### 9.2 Detailed Drug Profiles
---
#### DRUG 1: N-ACETYLCYSTEINE (NAC)
**Class:** Antidote; Glutathione precursor; Cytoprotective agent
**Short Introduction:**
NAC is the drug of choice and accepted antidote for acetaminophen (paracetamol) overdose. It is also used in severe non-acetaminophen DILI and acute liver failure (ALF) to improve transplant-free survival.
**Mechanism of Action (Flowchart):**
```
PARACETAMOL OVERDOSE
│
▼
CYP2E1 / CYP3A4 Metabolism
│
▼
NAPQI (Toxic Metabolite)
│
▼
GLUTATHIONE STORES DEPLETED
│
NAC Administration
│
┌────┴────────────────────────┐
│ │
▼ ▼
REPLENISHES GSH DIRECTLY CONJUGATES
STORES WITH NAPQI
│ │
└────────────┬────────────────┘
▼
NAPQI DETOXIFIED - EXCRETED
│
▼
HEPATOCYTE INJURY PREVENTED
(Also reduces ROS, supports mitochondria)
```
**Indications:**
- Acetaminophen overdose (primary, gold standard indication)
- Non-acetaminophen ALF with early hepatic encephalopathy (grade I-II)
- Severe idiosyncratic DILI
**Dose:**
| Route | Regimen |
|---|---|
| **IV (Preferred for overdose)** | Loading: 150 mg/kg in 200 mL D5W over 60 min → 50 mg/kg over 4 hr → 100 mg/kg over 16 hr (Prescott 3-bag regimen) |
| **Oral** | 140 mg/kg loading dose, then 70 mg/kg every 4 hr × 17 doses |
| **Non-APAP ALF (IV)** | 150 mg/kg/day × 3 days |
**Contraindications:**
- Known hypersensitivity to NAC (rare)
- Use with caution in severe asthma (may trigger bronchospasm - especially inhalation route)
**Adverse Drug Reactions (ADRs):**
| ADR | Notes |
|---|---|
| Nausea / vomiting | Common with oral route |
| Anaphylactoid reaction | IV route - flushing, urticaria, bronchospasm (rate-dependent; slow infusion) |
| Hypotension | During IV loading dose |
| Rash | Mild |
**Drug Interactions:**
| Drug | Interaction |
|---|---|
| Activated charcoal | May reduce oral NAC absorption if given simultaneously (separate by at least 1 hr) |
| Nitroglycerin | NAC may potentiate hypotensive effect |
---
#### DRUG 2: URSODEOXYCHOLIC ACID (UDCA / Ursodiol)
**Class:** Cytoprotective hydrophilic bile acid; Hepatoprotective agent
**Short Introduction:**
UDCA is a naturally occurring secondary bile acid that replaces more toxic hydrophobic bile acids, protects hepatocyte and cholangiocyte membranes, and improves bile flow. Used for cholestatic DILI.
**Mechanism of Action (Flowchart):**
```
CHOLESTATIC DILI
(Toxic hydrophobic bile acids accumulate)
│
▼
UDCA Administration
│
┌────┴──────────────────────────┐
│ │ │
▼ ▼ ▼
DISPLACES STABILIZES IMMUNOMODULATION
TOXIC BILE HEPATOCYTE & (reduces HLA-I/II
ACIDS from CHOLANGIOCYTE expression, reduces
BILE MEMBRANES cytotoxic T-cell
│ response)
▼
IMPROVES BILE FLOW
(choleretic effect)
│
▼
REDUCES PRURITUS
HASTEN DILI RECOVERY
```
**Indications:**
- Cholestatic DILI - pruritus and cholestasis
- Chronic cholestasis following DILI
- Primary biliary cholangitis (cholestatic pattern DILI managed similarly)
- Antimicrobial-induced cholestatic injury (case series)
**Dose:**
- 13–15 mg/kg/day orally in 2–4 divided doses
- Duration: Until resolution of liver biochemistry (weeks to months)
**Contraindications:**
- Complete biliary obstruction (surgical cause must be excluded)
- Acute cholecystitis, biliary fistula
- Pregnancy: Relative caution (Category B)
**ADRs:**
| ADR | Notes |
|---|---|
| Diarrhea / loose stools | Dose-related; reduce dose |
| Pruritus initially | Transient worsening |
| Nausea | Mild |
| Hair loss (alopecia) | Rare |
**Drug Interactions:**
| Drug | Interaction |
|---|---|
| Cholestyramine / Antacids (Al, Mg) | Bind UDCA in GI tract → reduced absorption (separate by 2 hr) |
| Cyclosporine | UDCA may increase cyclosporine absorption |
---
#### DRUG 3: CORTICOSTEROIDS (Prednisolone / Prednisone / Methylprednisolone)
**Class:** Glucocorticoid; Anti-inflammatory; Immunosuppressant
**Short Introduction:**
Corticosteroids suppress immune-mediated and inflammatory mechanisms in DILI. They are the cornerstone treatment for hypersensitivity DILI, DRESS syndrome, autoimmune-featured DILI, and checkpoint inhibitor (anti-PD-1/CTLA-4) hepatitis.
**Mechanism of Action (Flowchart):**
```
IMMUNE-MEDIATED DILI
(Drug hapten → T-cell activation → cytokine storm)
│
▼
CORTICOSTEROID
│
┌────┴──────────────────────────────────┐
│ │
▼ ▼
BINDS GLUCOCORTICOID RECEPTOR INHIBITS NF-κB
(cytoplasmic GCR) PATHWAY
│ │
▼ ▼
TRANSLOCATES TO NUCLEUS REDUCES TNF-α, IL-1,
│ IL-6, IL-12
▼
INHIBITS INFLAMMATORY GENES
(COX-2, iNOS, inflammatory cytokines)
│
▼
REDUCES HEPATIC INFLAMMATION
& IMMUNE-MEDIATED HEPATOCYTE INJURY
```
**Indications:**
- DRESS syndrome with hepatic involvement
- Autoimmune-featured DILI (biopsy-confirmed interface hepatitis)
- Checkpoint inhibitor (anti-PD-1, anti-CTLA-4) hepatitis (immune-related adverse event)
- Severe hypersensitivity reactions with systemic features
**Dose:**
| Indication | Dose |
|---|---|
| Hypersensitivity DILI | Prednisolone 0.5–1 mg/kg/day × 2–4 weeks, then taper |
| DRESS with liver involvement | Prednisolone 1–2 mg/kg/day; continue until resolution, gradual taper |
| Checkpoint inhibitor hepatitis (Grade 3–4) | Methylprednisolone 1–2 mg/kg/day IV, taper over weeks |
| Autoimmune-featured DILI | Prednisolone 0.5 mg/kg/day with taper |
**Contraindications:**
- Active systemic infection (untreated)
- Active GI bleeding / peptic ulcer (relative)
- Non-immune-mediated DILI (no clear benefit; may be harmful in severe non-autoimmune DILI)
- Uncontrolled diabetes (relative contraindication)
**ADRs (with prolonged use):**
| System | ADRs |
|---|---|
| Metabolic | Hyperglycemia, weight gain, fluid retention |
| Infection | Opportunistic infections (TB reactivation, fungal) |
| GI | Peptic ulcer, GI bleed |
| Bone | Osteoporosis, avascular necrosis |
| CNS | Mood changes, insomnia, psychosis |
| Adrenal | HPA axis suppression if abruptly stopped |
**Drug Interactions:**
| Drug | Interaction |
|---|---|
| NSAIDs | Increased GI bleeding risk |
| Antidiabetics | Reduced hypoglycemic effect (hyperglycemia) |
| Vaccines (live) | Avoid during immunosuppression |
| CYP3A4 inhibitors (azoles, macrolides) | Increase corticosteroid levels |
| Rifampicin | Reduces corticosteroid levels (enzyme inducer) |
---
#### DRUG 4: CHOLESTYRAMINE
**Class:** Bile acid sequestrant (anion exchange resin)
**Short Introduction:**
Cholestyramine is an ion-exchange resin that binds bile acids in the GI tract, preventing their reabsorption. It relieves pruritus in cholestatic DILI and is specifically useful for leflunomide hepatotoxicity due to its ability to interrupt enterohepatic circulation.
**Mechanism of Action (Flowchart):**
```
CHOLESTATIC DILI / PRURITUS
│
▼
BILE ACIDS accumulate in blood & skin
→ pruritus
│
CHOLESTYRAMINE (Oral)
│
▼
Binds bile acids in GI lumen
(ion exchange resin)
│
▼
INTERRUPTS ENTEROHEPATIC CIRCULATION
│
▼
REDUCES BILE ACID POOL IN BLOOD
│
▼
RELIEVES PRURITUS
```
**Special Use - Leflunomide Toxicity:**
Leflunomide has a prolonged half-life (t½ ~2 weeks) due to extensive enterohepatic circulation. Cholestyramine accelerates its elimination:
- Dose: 8 g TID × 11 days to accelerate leflunomide washout
**Standard Dose (Pruritus):**
- 4 g (one packet) 2–4 times daily with meals; maximum 24 g/day
**Contraindications:**
- Complete biliary obstruction (no bile in gut to bind)
- Bowel obstruction
- Phenylketonuria (some formulations contain aspartame)
**ADRs:**
| ADR | Notes |
|---|---|
| Constipation | Most common; use with adequate fluid |
| Bloating / flatulence | Common |
| Nausea | Mild |
| Fat-soluble vitamin deficiency | Vitamins A, D, E, K with prolonged use |
**Drug Interactions:**
| Drug | Interaction |
|---|---|
| UDCA, warfarin, digoxin, thyroid hormones, statins, fat-soluble vitamins | Cholestyramine binds all → reduced absorption. Administer other drugs 1 hr BEFORE or 4–6 hr AFTER cholestyramine |
---
#### DRUG 5: L-CARNITINE
**Class:** Nutritional supplement / metabolic cofactor
**Short Introduction:**
L-Carnitine is an amino acid derivative essential for fatty acid transport into mitochondria. It is specifically indicated for valproic acid (valproate)-induced hepatotoxicity and hyperammonemia in children, where carnitine deficiency is a key pathogenic mechanism.
**Mechanism of Action (Flowchart):**
```
VALPROIC ACID HEPATOTOXICITY
│
▼
Valproate inhibits mitochondrial β-oxidation
│
▼
Carnitine deficiency
(Valproate sequentially depletes free carnitine)
│
L-CARNITINE Supplementation
│
▼
RESTORES mitochondrial fatty acid transport
│
▼
REDUCES toxic acylcarnitine accumulation
│
▼
REDUCES AMMONIA levels
│
▼
HEPATOCYTE PROTECTION
```
**Indication:**
- Valproate-induced hepatotoxicity with hyperammonemia (especially children)
**Dose:**
- IV: 100 mg/kg/day (max 3 g/day) in acute hyperammonemia
- Oral: 50–100 mg/kg/day in divided doses for maintenance
**Contraindications:**
- Known hypersensitivity to L-carnitine
**ADRs:**
- Nausea, vomiting, diarrhea (oral)
- Fishy body odor
- Seizures reported (use caution in seizure disorders)
**Drug Interactions:**
- Valproic acid: Carnitine reverses valproate-induced depletion (therapeutic purpose)
---
#### DRUG 6: LACTULOSE (for complication - Hepatic Encephalopathy)
**Class:** Osmotic laxative / Ammonia-lowering agent
**Short Introduction:**
Lactulose acidifies colonic contents and traps ammonium (NH4+), reducing ammonia absorption. Used to manage hepatic encephalopathy (HE) that complicates ALF from DILI.
**MOA:**
```
Lactulose (non-absorbable disaccharide)
│
▼
Colonic bacteria convert to lactic acid / acetic acid
│
▼
ACIDIFICATION of colon (pH ↓)
│
▼
NH3 → NH4+ (trapped, non-absorbable)
│
▼
OSMOTIC LAXATIVE EFFECT
(increases stool frequency → ammonia excreted)
│
▼
REDUCES SERUM AMMONIA → IMPROVES HE
```
**Dose:**
- Oral: 15–30 mL (10–20 g) 2–4 times daily; titrate to 2–3 soft stools/day
- Rectal (enema): 300 mL + 700 mL water for acute severe HE
**ADRs:** Bloating, flatulence, cramping, diarrhea (dose-limiting)
**Interactions:** Neomycin (additive effect); antacids may reduce efficacy
---
## 10. PHARMACOLOGICAL TREATMENT SUMMARY CHART
| Drug | Class | MOA (Brief) | Indication in DILI | Dose | ADRs | Contraindications | Key Drug Interaction |
|---|---|---|---|---|---|---|---|
| **N-Acetylcysteine (NAC)** | Glutathione precursor / Antidote | Replenishes GSH; directly conjugates NAPQI; reduces ROS | Paracetamol overdose; non-APAP ALF | IV: 150→50→100 mg/kg (3-bag); Oral: 140 mg/kg load | Anaphylactoid (IV), nausea, vomiting | NAC allergy; severe asthma | Activated charcoal (separate doses) |
| **Ursodeoxycholic Acid (UDCA)** | Cytoprotective bile acid | Displaces toxic bile acids; stabilizes membranes; choleretic; immunomodulatory | Cholestatic DILI; pruritus | 13–15 mg/kg/day PO in divided doses | Diarrhea, nausea, transient pruritus | Complete biliary obstruction | Cholestyramine/antacids reduce UDCA absorption |
| **Prednisolone/Methylprednisolone** | Glucocorticoid | Binds GCR; inhibits NF-κB; reduces inflammatory cytokines; suppresses T-cell response | Hypersensitivity DILI; DRESS; checkpoint inhibitor hepatitis; autoimmune-featured DILI | Prednisolone 0.5–2 mg/kg/day PO; Methylprednisolone 1–2 mg/kg/day IV | Hyperglycemia, infection, GI bleed, osteoporosis | Active untreated infection; non-immune DILI | NSAIDs (GI bleed); rifampicin (↓ steroid levels); CYP3A4 inhibitors (↑ levels) |
| **Cholestyramine** | Bile acid sequestrant | Ion-exchange resin; binds bile acids in GI lumen; interrupts enterohepatic circulation | Pruritus in cholestatic DILI; leflunomide hepatotoxicity washout | 4 g 2–4× daily; Leflunomide washout: 8 g TID × 11 days | Constipation, bloating, fat-soluble vitamin deficiency | Complete biliary obstruction; bowel obstruction | Reduces absorption of most drugs - give other drugs 1 hr before or 4–6 hr after |
| **L-Carnitine** | Metabolic cofactor | Restores mitochondrial fatty acid transport; reduces toxic acylcarnitine; lowers ammonia | Valproate-induced hepatotoxicity + hyperammonemia | IV: 100 mg/kg/day (max 3g); Oral: 50–100 mg/kg/day | Nausea, fishy odor, diarrhea | Hypersensitivity | Valproic acid (therapeutic reversal) |
| **Lactulose** | Osmotic laxative | Acidifies colon; traps NH4+; osmotic catharsis | Hepatic encephalopathy complicating DILI/ALF | 15–30 mL 2–4× daily (titrate to 2–3 stools/day) | Bloating, flatulence, cramping, diarrhea | Galactosaemia; bowel obstruction | Antacids reduce efficacy; neomycin: additive |
| **Rifaximin** | Non-absorbable antibiotic | Reduces urease-producing gut bacteria → ↓ ammonia production | Hepatic encephalopathy (as adjunct or alternative to lactulose) | 550 mg PO BID | Nausea, abdominal pain (mild) | Bowel obstruction | Minimal (low systemic absorption) |
| **Diphenhydramine** | Antihistamine (H1 blocker) | Blocks H1 receptors; sedation; reduces perception of itch | Symptomatic pruritus | 25–50 mg PO/IV q4–6h PRN | Sedation, anticholinergic effects | Closed-angle glaucoma; BPH | CNS depressants (additive sedation) |
---
## 11. DRUG INTERACTIONS SUMMARY
| Object Drug | Precipitant Drug | Effect | Management |
|---|---|---|---|
| UDCA | Cholestyramine | ↓ UDCA absorption | Separate by 2 hours |
| UDCA | Antacids (Mg, Al) | ↓ UDCA absorption | Separate by 2 hours |
| Oral NAC | Activated charcoal | ↓ NAC absorption | Separate by ≥1 hr; prefer IV NAC with charcoal |
| Prednisolone | Rifampicin | ↓ Steroid levels (CYP3A4 induction) | Increase steroid dose or avoid |
| Prednisolone | Azole antifungals | ↑ Steroid levels (CYP3A4 inhibition) | Monitor; reduce steroid dose |
| Prednisolone | NSAIDs | ↑ GI bleeding risk | Avoid; use PPI prophylaxis |
| Cholestyramine | Warfarin, digoxin, levothyroxine, statins, fat-soluble vitamins | ↓ Absorption of all | Administer other drugs 1 hr before or 4–6 hr after |
| Cyclosporine | UDCA | ↑ Cyclosporine absorption | Monitor cyclosporine levels |
| L-Carnitine | Valproic acid | Reduces valproate-induced depletion | Therapeutic use |
---
## 12. SPECIAL CONSIDERATIONS
### Hy's Law and Prognosis
- ALT > 3× ULN + Total Bilirubin > 2× ULN (in absence of cholestasis) = ~10% mortality
- This is "Hy's Law" - a critical prognostic marker in DILI
### Acute Liver Failure Criteria (King's College):
- Transfer to liver transplant center if:
- INR > 6.5, OR
- Any 3 of: age <10 or >40 years, non-A non-B hepatitis or drug etiology, jaundice onset to encephalopathy >7 days, INR >3.5, bilirubin >300 µmol/L
### Chronic DILI
- Acute DILI (<3 months) progresses to chronic liver injury in 5–10% of cases
- Defined as persistence of liver injury >3 months after stopping the drug
- Histologic patterns: chronic hepatitis, cirrhosis, vanishing bile duct syndrome
---
## 13. SUMMARY (Quick Revision)
| Feature | Key Point |
|---|---|
| **Definition** | Liver injury by drugs/xenobiotics; threshold: ALT >3× or ALP >2× ULN |
| **Types** | Intrinsic (dose-dependent, predictable) vs. Idiosyncratic (unpredictable) |
| **Most common cause** | Acetaminophen (intrinsic); Amoxicillin-clavulanate, isoniazid (idiosyncratic) |
| **Most common cause of ALF** | Acetaminophen (50% of ALF in USA) |
| **Diagnosis** | Exclusion + RUCAM causality assessment + temporal relationship |
| **R Ratio** | ALT/ULN ÷ ALP/ULN: >5 hepatocellular; <2 cholestatic; 2–5 mixed |
| **Hy's Law** | ALT >3× + Bili >2× = ~10% mortality |
| **FIRST step in treatment** | STOP the offending drug immediately |
| **Antidote for APAP** | N-Acetylcysteine (NAC) - IV or oral |
| **Cholestatic pruritus** | UDCA + Cholestyramine |
| **Immune/hypersensitivity DILI** | Corticosteroids (Prednisolone) |
| **Valproate toxicity** | L-Carnitine |
| **Hepatic encephalopathy** | Lactulose ± Rifaximin |
| **ALF unresponsive to treatment** | Liver transplantation |
| **Causality tool** | RUCAM (Roussel Uclaf Causality Assessment Method) |
---
## REFERENCES
- Goldman-Cecil Medicine, International Edition (9780323930345) - Chapter 136: Drug-Induced Liver Injury
- Washington Manual of Medical Therapeutics (9781975190620) - DILI section
- Yamada's Textbook of Gastroenterology, 7th Edition (9781119600169) - Chapter 89
- Robbins & Cotran Pathologic Basis of Disease (9780443264528)
- Goodman & Gilman's Pharmacological Basis of Therapeutics (9781264258079)
- Harrison's Principles of Internal Medicine, 22E (9781265977061)
- Lippincott's Illustrated Reviews: Pharmacology (9781975170561)
- Ozturk et al. (2025). Drug-induced liver injury: Diagnosis, management and the role of liver transplantation. *Hepatology Forum*. PMID: 40248678
- Hosack et al. (2023). Drug-induced liver injury: a comprehensive review. *Ther Adv Gastroenterol*. PMID: 36968618
- PharmdGuru.com - Drug Induced Liver Disorders (https://pharmdguru.com/6-drug-induced-liver-disorders/)
- AASLD Practice Guidance on DILI (2023)
- EASL Clinical Practice Guidelines: DILI (2019)
---
*Notes prepared for Therapeutics 3 | Date: August 2026*
cd /tmp/workspace/DILI-notes && python3 << 'EOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm, mm from reportlab.lib import colors from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, PageBreak, KeepTogether from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY from reportlab.platypus.flowables import KeepTogether # Setup doc = SimpleDocTemplate( "Drug_Induced_Liver_Disorders_Therapeutics3.pdf", pagesize=A4, rightMargin=1.8*cm, leftMargin=1.8*cm, topMargin=2*cm, bottomMargin=2*cm ) styles = getSampleStyleSheet() # Custom styles title_style = ParagraphStyle('Title', parent=styles['Title'], fontSize=20, textColor=colors.HexColor('#1a237e'), spaceAfter=6, alignment=TA_CENTER, fontName='Helvetica-Bold') subtitle_style = ParagraphStyle('Subtitle', parent=styles['Normal'], fontSize=11, textColor=colors.HexColor('#4a4a4a'), spaceAfter=12, alignment=TA_CENTER) h1_style = ParagraphStyle('H1', parent=styles['Heading1'], fontSize=14, textColor=colors.white, backColor=colors.HexColor('#1a237e'), spaceAfter=4, spaceBefore=14, fontName='Helvetica-Bold', leftIndent=-5, rightIndent=-5, leading=20, borderPad=5) h2_style = ParagraphStyle('H2', parent=styles['Heading2'], fontSize=12, textColor=colors.HexColor('#1a237e'), spaceAfter=4, spaceBefore=10, fontName='Helvetica-Bold', borderPad=2) h3_style = ParagraphStyle('H3', parent=styles['Heading3'], fontSize=11, textColor=colors.HexColor('#0d47a1'), spaceAfter=3, spaceBefore=8, fontName='Helvetica-Bold') body_style = ParagraphStyle('Body', parent=styles['Normal'], fontSize=9.5, spaceAfter=4, leading=14, alignment=TA_JUSTIFY) bullet_style = ParagraphStyle('Bullet', parent=styles['Normal'], fontSize=9.5, spaceAfter=3, leading=13, leftIndent=12, bulletIndent=2) box_style = ParagraphStyle('Box', parent=styles['Normal'], fontSize=10, spaceAfter=4, leading=14, backColor=colors.HexColor('#e3f2fd'), leftIndent=10, rightIndent=10, borderPad=8, fontName='Helvetica-Bold') note_style = ParagraphStyle('Note', parent=styles['Normal'], fontSize=9, spaceAfter=3, leading=12, backColor=colors.HexColor('#fff9c4'), leftIndent=10, rightIndent=10, borderPad=6) drug_header_style = ParagraphStyle('DrugHeader', parent=styles['Normal'], fontSize=12, textColor=colors.white, backColor=colors.HexColor('#0d47a1'), spaceAfter=4, spaceBefore=12, fontName='Helvetica-Bold', borderPad=6, alignment=TA_CENTER) code_style = ParagraphStyle('Code', parent=styles['Normal'], fontSize=8.5, fontName='Courier', backColor=colors.HexColor('#f5f5f5'), spaceAfter=4, leading=13, leftIndent=8, rightIndent=8, borderPad=5) story = [] def tbl(data, col_widths, header_bg=colors.HexColor('#1565c0'), alt_bg=colors.HexColor('#e8f4f8')): """Create a styled table""" t = Table(data, colWidths=col_widths, repeatRows=1) style_cmds = [ ('BACKGROUND', (0,0), (-1,0), header_bg), ('TEXTCOLOR', (0,0), (-1,0), colors.white), ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'), ('FONTSIZE', (0,0), (-1,0), 9), ('ALIGN', (0,0), (-1,-1), 'LEFT'), ('VALIGN', (0,0), (-1,-1), 'TOP'), ('FONTNAME', (0,1), (-1,-1), 'Helvetica'), ('FONTSIZE', (0,1), (-1,-1), 8.5), ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.white, alt_bg]), ('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#b0bec5')), ('TOPPADDING', (0,0), (-1,-1), 4), ('BOTTOMPADDING', (0,0), (-1,-1), 4), ('LEFTPADDING', (0,0), (-1,-1), 5), ('RIGHTPADDING', (0,0), (-1,-1), 5), ('WORDWRAP', (0,0), (-1,-1), 'CJK'), ] t.setStyle(TableStyle(style_cmds)) return t PAGE_W = A4[0] - 3.6*cm # usable width # ============================================================ # TITLE PAGE # ============================================================ story.append(Spacer(1, 1*cm)) story.append(Paragraph("DRUG-INDUCED LIVER DISORDERS (DILI)", title_style)) story.append(Paragraph("Therapeutics 3 — Comprehensive Study Notes", subtitle_style)) story.append(HRFlowable(width="100%", thickness=3, color=colors.HexColor('#1a237e'), spaceAfter=4)) story.append(Paragraph("Sources: Goldman-Cecil Medicine | Washington Manual | Yamada's Gastroenterology | Robbins Pathology | PharmdGuru.com | AASLD/EASL Guidelines 2023-2025", ParagraphStyle('src', parent=styles['Normal'], fontSize=8, textColor=colors.gray, alignment=TA_CENTER))) story.append(Spacer(1, 0.5*cm)) # ============================================================ # 1. INTRODUCTION # ============================================================ story.append(Paragraph("1. INTRODUCTION", h1_style)) story.append(Spacer(1, 3)) story.append(Paragraph( "The liver is the primary site of drug metabolism, making it uniquely vulnerable to toxic injury. " "Drug-Induced Liver Injury (DILI) is one of the most serious adverse drug reactions and a leading cause of " "acute liver failure (ALF), post-marketing drug withdrawals, and drug development failures.", body_style)) intro_data = [ ['Key Fact', 'Detail'], ['DILI % of ALF (USA)', '~50% of all cases of Acute Liver Failure'], ['Most common cause', 'Acetaminophen (Paracetamol) — intrinsic/dose-dependent'], ['Drugs implicated', '>1,000 drugs, herbals, dietary supplements (NIH LiverTox database)'], ['True incidence', 'May be 10× higher than reported; <20/100,000 person-years in Western countries'], ['Leading idiosyncratic cause', 'Amoxicillin-clavulanate (Western); herbal medicines (Asian countries)'], ['Acute → Chronic progression', '5–10% of acute DILI cases progress to chronic liver injury'], ] story.append(tbl(intro_data, [5.5*cm, PAGE_W-5.5*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 2. DEFINITION # ============================================================ story.append(Paragraph("2. DEFINITION", h1_style)) story.append(Spacer(1, 3)) story.append(Paragraph( '<b>Drug-Induced Liver Injury (DILI)</b> is liver damage caused by drugs, herbal products, dietary supplements, ' 'or chemicals, defined by threshold elevations in liver chemistry tests (when other etiologies have been excluded). ' 'Clinical presentation can be hepatocellular, cholestatic, or mixed, as defined by the R ratio.', body_style)) def_data = [ ['Marker', 'Threshold', 'Significance'], ['ALT or AST', '> 3× ULN', 'Hepatocellular injury marker'], ['ALP', '> 2× ULN', 'Cholestatic injury marker'], ['Total Bilirubin', '> 2× ULN', 'Bilirubin excretion impaired'], ['GGT', 'Elevated', 'Confirmatory (cholestasis/hepatotoxicity)'], ] story.append(Paragraph("Biochemical Threshold Criteria:", h3_style)) story.append(tbl(def_data, [4*cm, 3.5*cm, PAGE_W-7.5*cm])) story.append(Spacer(1, 0.2*cm)) r_data = [ ['R Ratio = (ALT/ULN) ÷ (ALP/ULN)', 'Pattern', 'Injury Type'], ['R > 5', 'Hepatocellular', 'Hepatocyte death (ALT >> ALP)'], ['R < 2', 'Cholestatic', 'Bile duct/cholangiocyte injury (ALP >> ALT)'], ['R 2–5', 'Mixed', 'Combined hepatocellular + cholestatic'], ] story.append(Paragraph("Pattern Classification (R Ratio):", h3_style)) story.append(tbl(r_data, [5*cm, 4*cm, PAGE_W-9*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 3. ETIOLOGY # ============================================================ story.append(Paragraph("3. ETIOLOGY — Common Hepatotoxic Drugs", h1_style)) story.append(Spacer(1, 3)) etio_data = [ ['Drug Class', 'Examples', 'Type of Injury'], ['Analgesics / Antipyretics', 'Acetaminophen, Aspirin, Diclofenac, Sulindac', 'Intrinsic (dose-dependent); hepatocellular'], ['Antitubercular drugs', 'Isoniazid (INH), Rifampicin, Pyrazinamide', 'Idiosyncratic; hepatocellular / mixed'], ['Antibiotics', 'Amoxicillin-clavulanate, Tetracyclines, Nitrofurantoin, Erythromycin', 'Cholestatic / mixed (most common idiosyncratic)'], ['Anticonvulsants', 'Phenytoin, Carbamazepine, Valproic acid', 'Idiosyncratic; hepatocellular'], ['Antifungals', 'Ketoconazole, Fluconazole, Itraconazole', 'Idiosyncratic; hepatocellular / cholestatic'], ['Antivirals / ARVs', 'Nevirapine, HAART regimens', 'Idiosyncratic; hepatocellular'], ['Cardiovascular', 'Amiodarone, Statins, Methyldopa, Hydralazine', 'Idiosyncratic; steatohepatitis / mixed'], ['Immunosuppressants', 'Methotrexate, Azathioprine, Leflunomide', 'Fibrosis (MTX); cholestatic (AZA)'], ['Checkpoint inhibitors', 'Nivolumab, Pembrolizumab, Ipilimumab', 'Immune-mediated (indirect hepatotoxicity)'], ['Herbal / Supplements', 'Kava, Green tea extract, Pyrrolizidine alkaloids, Black cohosh', 'Variable; hepatocellular / venoocclusive'], ['Antidiabetics', 'Troglitazone (withdrawn), Pioglitazone', 'Idiosyncratic (rare)'], ] story.append(tbl(etio_data, [4*cm, 6*cm, PAGE_W-10*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 4. PATHOPHYSIOLOGY FLOWCHART # ============================================================ story.append(PageBreak()) story.append(Paragraph("4. PATHOPHYSIOLOGY", h1_style)) story.append(Spacer(1, 3)) # Types of injury story.append(Paragraph("4.1 Types of Drug-Induced Liver Injury", h2_style)) types_data = [ ['Feature', 'Intrinsic (Direct)', 'Idiosyncratic', 'Indirect'], ['Dose-dependence', 'Yes — predictable', 'No — unpredictable', 'No — via drug action'], ['Incidence', 'High (affects all exposed at toxic dose)', '<1:1,000 treated patients', 'Variable (increasing)'], ['Latency', 'Hours to days', 'Days to months', 'Days to weeks'], ['Example drug', 'Acetaminophen, CCl4', 'INH, Halothane, Diclofenac', 'Checkpoint inhibitors'], ['Mechanism', 'Direct cell toxicity by drug/metabolite', 'Metabolic or immune-mediated', 'Therapeutic immune activation'], ['Animal model', 'Reproducible', 'Not reproducible', 'Partially reproducible'], ] story.append(tbl(types_data, [4*cm, 4.5*cm, 4.5*cm, PAGE_W-13*cm])) story.append(Spacer(1, 0.3*cm)) story.append(Paragraph("4.2 Pathophysiology Flowchart", h2_style)) fc_lines = [ "DRUG ADMINISTRATION", "↓", "Hepatic Uptake & Metabolism (CYP450 enzymes — CYP2E1, CYP3A4)", "↓", "REACTIVE METABOLITE FORMATION", "↓ ↓", "INTRINSIC MECHANISM IDIOSYNCRATIC MECHANISM", "(Dose-dependent) (Rare, unpredictable)", "↓ ↓", "NAPQI (from paracetamol) Hapten Formation / Immune Activation", "↓ ↓", "GLUTATHIONE DEPLETION T-Cell Activation / Cytokine Storm", "↓ ↓", "Covalent protein binding TNF-α ↑, IL-1 ↑, IL-6 ↑", "↓ ↓", "MITOCHONDRIAL DYSFUNCTION ← ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘", "↓", "OXIDATIVE STRESS (ROS↑) + ATP Depletion", "↓", "HEPATOCYTE NECROSIS / APOPTOSIS", "↓", "PATTERNS OF LIVER INJURY:", "• Hepatocellular (zone 3 necrosis)", "• Cholestatic (bile duct injury, BSEP inhibition)", "• Mixed", "• Steatosis / Steatohepatitis", "• Fibrosis / Cirrhosis", "• Vascular injury (sinusoidal obstruction syndrome)", ] for line in fc_lines: story.append(Paragraph(line, code_style)) story.append(Spacer(1, 0.3*cm)) story.append(Paragraph("Key Molecular Mechanisms:", h3_style)) mech_data = [ ['Mechanism', 'Details', 'Example Drug'], ['CYP450 toxic metabolite', 'CYP2E1/3A4 converts drug → reactive NAPQI; depletes hepatic GSH', 'Acetaminophen'], ['Mitochondrial dysfunction', 'ROS generation, electron transport inhibition, mtDNA damage', 'Valproic acid, Tetracyclines'], ['Hapten formation', 'Reactive metabolite binds protein → neoantigens → immune response', 'Halothane, Tienilic acid'], ['BSEP inhibition', 'Bile salt export pump blocked → cholestasis', 'Troglitazone, Cyclosporine'], ['HLA-restricted immune activation', 'Drug binds MHC protein → specific T-cell cytotoxicity', 'Flucloxacillin, Abacavir'], ['Innate immune activation', 'DAMP release → Kupffer cell activation → TNF-α/IL-1β release', 'Multiple drugs (second hit)'], ] story.append(tbl(mech_data, [3.5*cm, 7*cm, PAGE_W-10.5*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 5. CLINICAL FEATURES # ============================================================ story.append(PageBreak()) story.append(Paragraph("5. CLINICAL FEATURES", h1_style)) story.append(Spacer(1, 3)) cf_data = [ ['Category', 'Symptom / Sign', 'Notes'], ['General', 'Fatigue, Malaise', 'Most common early symptoms'], ['General', 'Nausea & Vomiting', 'Common, especially hepatocellular injury'], ['General', 'Anorexia', 'Loss of appetite'], ['General', 'Fever, Rash, Eosinophilia', 'Hypersensitivity pattern (immune-mediated)'], ['Hepatic', 'Jaundice (icterus)', 'Elevated bilirubin; indicates significant injury'], ['Hepatic', 'Dark urine (bilirubinuria)', 'Conjugated hyperbilirubinemia'], ['Hepatic', 'Pale/acholic stools', 'Cholestatic injury — bile flow obstruction'], ['Hepatic', 'Pruritus (itching)', 'Cholestatic injury — bile salts in skin'], ['Hepatic', 'RUQ pain / hepatomegaly', 'Hepatic inflammation or steatosis'], ['Severe/ALF', 'Coagulopathy (↑PT/INR)', 'Loss of hepatic synthetic function'], ['Severe/ALF', 'Hepatic encephalopathy', 'Asterixis, confusion, coma — ALF'], ['Severe/ALF', 'Ascites', 'Portal hypertension / hypoalbuminemia'], ['Severe/ALF', 'Peripheral edema', 'Hypoalbuminemia'], ['Severe/ALF', 'GI bleeding', 'Variceal hemorrhage in advanced disease'], ['DRESS Syndrome', 'Rash + fever + lymphadenopathy + eosinophilia + multiorgan', 'Drug-specific immune reaction; requires steroids'], ] story.append(tbl(cf_data, [3.2*cm, 4.5*cm, PAGE_W-7.7*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 6. DIAGNOSIS # ============================================================ story.append(Paragraph("6. DIAGNOSIS", h1_style)) story.append(Spacer(1, 3)) story.append(Paragraph( '<b>DILI is a diagnosis of exclusion.</b> All other causes of liver disease must be ruled out. ' 'Establishing a temporal relationship between drug exposure and onset of liver injury is essential. ' 'RUCAM causality assessment is the standard tool.', body_style)) story.append(Paragraph("6.1 Diagnostic Tests", h2_style)) diag_data = [ ['Test', 'Pattern', 'Notes'], ['ALT / AST (elevated >3× ULN)', 'Hepatocellular', 'Hepatocyte damage'], ['ALP (elevated >2× ULN)', 'Cholestatic', 'Biliary epithelium injury'], ['GGT (elevated)', 'Both patterns', 'Sensitive but non-specific'], ['Total Bilirubin (elevated)', 'Any', 'Hy\'s Law if bilirubin >2× ULN + ALT >3× ULN'], ['PT / INR (prolonged)', 'Severe', 'Synthetic dysfunction; marker of ALF severity'], ['Serum Albumin (low)', 'Chronic/severe', 'Chronic synthetic dysfunction'], ['CBC with differential', 'Any', 'Eosinophilia → hypersensitivity; thrombocytopenia → portal hypertension'], ['Hepatitis A IgM', 'Exclusion', 'Rule out acute HAV'], ['HBsAg, anti-HBc IgM, HCV RNA', 'Exclusion', 'Rule out viral hepatitis B/C'], ['ANA, ASMA, anti-LKM', 'Exclusion', 'Rule out autoimmune hepatitis'], ['Ceruloplasmin + copper', 'Exclusion', 'Rule out Wilson\'s disease (young patients)'], ['Abdominal USG/CT/MRI', 'Imaging', 'Rule out biliary obstruction, portal hypertension'], ['Liver biopsy', 'Uncertain cases', 'Grade injury severity, exclude competing diagnoses'], ] story.append(tbl(diag_data, [5.5*cm, 3.5*cm, PAGE_W-9*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("6.2 RUCAM Causality Assessment", h2_style)) rucam_data = [ ['RUCAM Score', 'Causality Probability'], ['> 8', 'Highly probable'], ['6 – 8', 'Probable'], ['3 – 5', 'Possible'], ['1 – 2', 'Unlikely'], ['≤ 0', 'Excluded'], ] story.append(tbl(rucam_data, [4*cm, PAGE_W-4*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "<b>RUCAM Parameters scored:</b> Time to onset, course after stopping drug, risk factors (age, alcohol), " "concomitant drugs, exclusion of non-drug causes, prior information about drug hepatotoxicity, rechallenge result.", body_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "⚠️ <b>Hy's Law:</b> ALT > 3× ULN + Total Bilirubin > 2× ULN (without cholestasis) = approximately 10% mortality risk. " "These patients require urgent escalation of care and transplant evaluation.", note_style)) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 7. TREATMENT GOALS # ============================================================ story.append(PageBreak()) story.append(Paragraph("7. TREATMENT GOALS", h1_style)) story.append(Spacer(1, 3)) goals_data = [ ['Priority', 'Goal', 'Action'], ['1 (IMMEDIATE)', 'Stop hepatic injury', 'Discontinue offending drug immediately'], ['2', 'Prevent progression to ALF', 'Monitor LFTs, INR, bilirubin, clinical status closely'], ['3', 'Symptomatic relief', 'Treat nausea, pruritus, encephalopathy, pain'], ['4', 'Prevent complications', 'Manage coagulopathy, ascites, HE, infections'], ['5', 'Specific antidote / therapy', 'NAC for paracetamol; L-carnitine for valproate; steroids for immune DILI'], ['6', 'Prevent recurrence', 'Avoid re-exposure; document allergy; educate patient'], ['7 (Last resort)', 'Liver transplantation', 'If ALF fails medical therapy — early transplant evaluation'], ] story.append(tbl(goals_data, [3*cm, 4.5*cm, PAGE_W-7.5*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 8. NON-PHARMACOLOGICAL TREATMENT # ============================================================ story.append(Paragraph("8. NON-PHARMACOLOGICAL TREATMENT", h1_style)) story.append(Spacer(1, 3)) nonpharm_data = [ ['Intervention', 'Details / Rationale'], ['Discontinue offending drug ★', 'MOST CRITICAL STEP. Majority of patients recover spontaneously after withdrawal. Do NOT rechallenge.'], ['GI Decontamination', 'Activated charcoal within 1–2 hours of acute ingestion (especially paracetamol). Gastric lavage if <1 hr.'], ['IV Fluid / Hydration', 'For nausea/vomiting, hypoglycemia, dehydration. Dextrose infusion for hypoglycemia in ALF.'], ['Nutritional Support', 'High calorie, high protein diet. Protein restriction only if severe HE (Grade III-IV). Enteral preferred over parenteral.'], ['Alcohol abstinence', 'Complete cessation — alcohol worsens liver injury and impairs recovery.'], ['Rest', 'Physical rest during acute phase. Reduce metabolic demand on liver.'], ['Avoid other hepatotoxins', 'NSAIDs, alcohol, herbal products, other potentially hepatotoxic drugs.'], ['Monitor closely', 'Serial LFTs (ALT, AST, ALP, bilirubin, PT/INR) every 1–3 days in acute/severe DILI.'], ['Hospitalization', 'Indicated for: high bilirubin, rising INR, encephalopathy, severe nausea/vomiting, Hy\'s law pattern.'], ['Liver transplant evaluation', 'Transfer to transplant center for ALF not responding to medical therapy. Early referral is critical.'], ['Patient education', 'Medication adherence, reporting symptoms, avoiding OTC/herbal self-medication, drug card/allergy documentation.'], ] story.append(tbl(nonpharm_data, [5*cm, PAGE_W-5*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # 9. PHARMACOLOGICAL TREATMENT # ============================================================ story.append(PageBreak()) story.append(Paragraph("9. PHARMACOLOGICAL TREATMENT", h1_style)) story.append(Spacer(1, 3)) story.append(Paragraph("Overview of Drugs Used in DILI Management:", h2_style)) overview_data = [ ['Drug', 'Class', 'Indication in DILI'], ['N-Acetylcysteine (NAC)', 'Antidote / GSH precursor', 'Paracetamol toxicity; severe non-APAP DILI/ALF'], ['Ursodeoxycholic Acid (UDCA)', 'Cytoprotective bile acid', 'Cholestatic DILI; pruritus; hasten recovery'], ['Cholestyramine', 'Bile acid sequestrant', 'Pruritus; leflunomide hepatotoxicity washout'], ['Corticosteroids (Prednisolone)', 'Glucocorticoid / Immunosuppressant', 'Hypersensitivity DILI; DRESS; checkpoint inhibitor hepatitis; autoimmune-featured DILI'], ['L-Carnitine', 'Metabolic cofactor', 'Valproic acid hepatotoxicity + hyperammonemia'], ['Lactulose', 'Osmotic laxative / Ammonia-lowering', 'Hepatic encephalopathy complicating DILI/ALF'], ['Rifaximin', 'Non-absorbable antibiotic', 'Hepatic encephalopathy (adjunct or alternative to lactulose)'], ['Diphenhydramine / Hydroxyzine', 'Antihistamine (H1 blocker)', 'Symptomatic pruritus'], ] story.append(tbl(overview_data, [5*cm, 4.5*cm, PAGE_W-9.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 1: NAC ─────────── story.append(Paragraph("DRUG 1: N-ACETYLCYSTEINE (NAC)", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Antidote; Glutathione Precursor; Cytoprotective Agent", body_style)) story.append(Paragraph( "<b>Introduction:</b> NAC is the gold-standard antidote for acetaminophen (paracetamol) overdose and the most important " "specific treatment in DILI. It replenishes depleted hepatic glutathione and directly detoxifies the toxic metabolite NAPQI. " "A randomized trial also showed improved transplant-free survival in non-acetaminophen ALF (especially early HE grades I-II).", body_style)) story.append(Paragraph("Mechanism of Action Flowchart:", h3_style)) nac_fc = [ "PARACETAMOL OVERDOSE → CYP2E1/CYP3A4 metabolism", "↓", "NAPQI (N-acetyl-p-benzoquinone imine) formed", "↓", "GLUTATHIONE (GSH) stores DEPLETED", "↓", "N-ACETYLCYSTEINE ADMINISTRATION", "↓ ↓", "REPLENISHES GSH DIRECTLY CONJUGATES WITH NAPQI", "↓ ↓", "NAPQI DETOXIFIED — excreted safely", "↓", "Also: ↓ ROS, supports mitochondria, anti-inflammatory effects", "↓", "HEPATOCYTE INJURY PREVENTED / REDUCED", ] for line in nac_fc: story.append(Paragraph(line, code_style)) nac_data = [ ['Parameter', 'Details'], ['Indications', '1. Acetaminophen overdose (primary indication)\n2. Non-APAP ALF with early hepatic encephalopathy (grade I-II)\n3. Severe idiosyncratic DILI'], ['Dose (IV)', 'Prescott 3-bag regimen:\n• 150 mg/kg in 200 mL D5W over 60 min (loading)\n• then 50 mg/kg over 4 hr\n• then 100 mg/kg over 16 hr\nContinue until paracetamol levels/INR normalize'], ['Dose (Oral)', '140 mg/kg loading dose, then 70 mg/kg every 4 hours × 17 doses (total 72 hr)'], ['Non-APAP ALF', 'IV NAC 150 mg/kg/day × 3 days (uncontrolled data; consider in all severe DILI/ALF)'], ['Contraindications', 'Known hypersensitivity to NAC (rare); caution in severe asthma (inhalation route)'], ['ADRs', 'IV: Anaphylactoid reaction (flushing, urticaria, bronchospasm — rate-dependent; slow infusion)\nOral: Nausea, vomiting, diarrhea; rash (mild)'], ['Drug Interactions', 'Activated charcoal: binds oral NAC → reduce absorption (separate by ≥1 hr; prefer IV)\nNitroglycerin: additive hypotension'], ] story.append(tbl(nac_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 2: UDCA ─────────── story.append(Paragraph("DRUG 2: URSODEOXYCHOLIC ACID (UDCA / Ursodiol)", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Cytoprotective Hydrophilic Bile Acid; Hepatoprotective Agent", body_style)) story.append(Paragraph( "<b>Introduction:</b> UDCA is a naturally occurring hydrophilic bile acid. It displaces toxic hydrophobic bile acids, " "stabilizes hepatocyte and cholangiocyte membranes, improves bile flow (choleretic effect), and has immunomodulatory " "properties. AASLD (2023) states it 'may improve symptoms of pruritus and hasten DILI recovery.'", body_style)) story.append(Paragraph("Mechanism of Action Flowchart:", h3_style)) udca_fc = [ "CHOLESTATIC DILI", "(Toxic hydrophobic bile acids accumulate in hepatocytes and bloodstream)", "↓", "UDCA administration (oral)", "↓ ↓ ↓", "DISPLACES STABILIZES IMMUNOMODULATION", "toxic bile hepatocyte (↓ HLA-I/II, ↓ T-cell", "acids membranes cytotoxicity, ↓ apoptosis)", "↓", "IMPROVED BILE FLOW (choleretic effect)", "↓", "↓ SERUM BILE ACIDS → RELIEVES PRURITUS", "↓ LIVER ENZYMES → HASTENS RECOVERY", ] for line in udca_fc: story.append(Paragraph(line, code_style)) udca_data = [ ['Parameter', 'Details'], ['Indications', 'Cholestatic DILI (pruritus, elevated ALP/GGT)\nChronic cholestasis following DILI\nAntimicrobial-induced cholestatic injury\nSteroid-resistant checkpoint inhibitor DILI (adjunct)'], ['Dose', '13–15 mg/kg/day orally in 2–4 divided doses\nDuration: Until resolution of liver biochemistry (weeks to months)'], ['Contraindications', 'Complete biliary obstruction (surgical cause must be excluded)\nAcute cholecystitis, biliary fistula'], ['ADRs', 'Diarrhea / loose stools (dose-related)\nNausea (mild)\nTransient worsening of pruritus initially\nAlopecia (rare)'], ['Drug Interactions', 'Cholestyramine/antacids (Al, Mg): bind UDCA → reduced absorption → separate by 2 hr\nCyclosporine: UDCA may increase cyclosporine absorption → monitor levels'], ] story.append(tbl(udca_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 3: Corticosteroids ─────────── story.append(PageBreak()) story.append(Paragraph("DRUG 3: CORTICOSTEROIDS (Prednisolone / Methylprednisolone)", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Glucocorticoid; Anti-inflammatory; Immunosuppressant", body_style)) story.append(Paragraph( "<b>Introduction:</b> Corticosteroids are the cornerstone of treatment for immune-mediated DILI. " "They suppress the inflammatory cascade, reduce cytokine-driven hepatocyte destruction, and are the mainstay for DRESS syndrome, " "checkpoint inhibitor hepatitis, and autoimmune-featured DILI. Their use in non-immune-mediated DILI is not supported and may be harmful.", body_style)) story.append(Paragraph("Mechanism of Action Flowchart:", h3_style)) cs_fc = [ "IMMUNE-MEDIATED DILI", "(Drug hapten → T-cell activation → Cytokine Storm: TNF-α↑, IL-1↑, IL-6↑)", "↓", "CORTICOSTEROID (Prednisolone/Methylprednisolone)", "↓", "Binds intracellular Glucocorticoid Receptor (GCR)", "↓", "Steroid-GCR complex translocates to nucleus", "↓ ↓", "Activates anti-inflammatory Inhibits NF-κB pathway", "gene transcription ↓", " ↓ TNF-α, IL-1β, IL-6, IL-12", " ↓ COX-2, iNOS", "↓", "REDUCED HEPATIC INFLAMMATION", "↓ Immune-mediated hepatocyte destruction → LIVER RECOVERY", ] for line in cs_fc: story.append(Paragraph(line, code_style)) cs_data = [ ['Parameter', 'Details'], ['Indications', 'DRESS syndrome with hepatic involvement\nAutoimmune-featured DILI (biopsy: interface hepatitis)\nCheckpoint inhibitor (anti-PD-1/anti-CTLA-4) hepatitis (Grade 3–4)\nSevere hypersensitivity reactions with systemic features'], ['Dose', 'Hypersensitivity DILI: Prednisolone 0.5–1 mg/kg/day × 2–4 weeks then gradual taper\nDRESS: Prednisolone 1–2 mg/kg/day; continue until resolution then taper\nCheckpoint inhibitor (Grade 3–4): Methylprednisolone 1–2 mg/kg/day IV → taper over weeks'], ['Contraindications', 'Active untreated systemic infection\nNon-immune-mediated DILI (no evidence of benefit, may worsen)\nActive GI bleeding / uncontrolled peptic ulcer (relative)'], ['ADRs', 'Hyperglycemia, weight gain, fluid retention\nOpportunistic infections (TB reactivation, fungal)\nPeptic ulcer / GI bleeding\nOsteoporosis, avascular necrosis (prolonged use)\nMood changes, insomnia, psychosis\nHPA axis suppression (if abrupt cessation)'], ['Drug Interactions', 'NSAIDs: ↑ GI bleeding risk — avoid or use PPI\nRifampicin: ↓ steroid levels (CYP3A4 inducer) — increase dose\nAzole antifungals / macrolides: ↑ steroid levels — monitor / reduce dose\nLive vaccines: avoid during immunosuppression\nAntidiabetics: reduced hypoglycemic effect (monitor glucose)'], ] story.append(tbl(cs_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 4: Cholestyramine ─────────── story.append(Paragraph("DRUG 4: CHOLESTYRAMINE", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Bile Acid Sequestrant (Anion Exchange Resin)", body_style)) story.append(Paragraph( "<b>Introduction:</b> Cholestyramine is an ion-exchange resin that binds bile acids in the GI tract, preventing reabsorption. " "It relieves pruritus in cholestatic DILI and has a specific use in leflunomide hepatotoxicity — it accelerates elimination " "of leflunomide by interrupting its enterohepatic circulation (leflunomide t½ ~2 weeks).", body_style)) story.append(Paragraph("Mechanism of Action Flowchart:", h3_style)) cho_fc = [ "CHOLESTATIC DILI / PRURITUS", "Bile acids accumulate in blood → skin deposition → PRURITUS", "↓", "CHOLESTYRAMINE (Oral — anion exchange resin)", "↓", "Binds bile acids in GI lumen (non-absorbable complex formed)", "↓", "Enterohepatic circulation INTERRUPTED", "↓", "↓ Bile acid pool in circulation → PRURITUS RELIEVED", "", "LEFLUNOMIDE WASHOUT USE:", "Cholestyramine 8g TID × 11 days", "↓ Leflunomide enterohepatic recycling → rapid drug elimination", ] for line in cho_fc: story.append(Paragraph(line, code_style)) cho_data = [ ['Parameter', 'Details'], ['Indications', 'Pruritus in cholestatic DILI\nLeflunomide hepatotoxicity (drug elimination)'], ['Dose', 'Pruritus: 4 g (1 packet) 2–4 times daily with meals (max 24 g/day)\nLeflunomide washout: 8 g TID × 11 days'], ['Contraindications', 'Complete biliary obstruction (no bile in gut)\nBowel obstruction\nPhenylketonuria (some formulations)'], ['ADRs', 'Constipation (most common — use with adequate fluid intake)\nBloating, flatulence, nausea\nFat-soluble vitamin deficiency (A, D, E, K) with prolonged use → supplement vitamins'], ['Drug Interactions', 'CRITICAL: Binds most drugs in GI tract → ↓ absorption of ALL co-administered drugs\nAffected drugs: UDCA, warfarin, digoxin, levothyroxine, statins, fat-soluble vitamins, oral contraceptives\nManagement: Take all other drugs 1 hr BEFORE or 4–6 hr AFTER cholestyramine'], ] story.append(tbl(cho_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 5: L-Carnitine ─────────── story.append(PageBreak()) story.append(Paragraph("DRUG 5: L-CARNITINE", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Nutritional Supplement / Metabolic Cofactor / Amino Acid Derivative", body_style)) story.append(Paragraph( "<b>Introduction:</b> L-Carnitine is an amino acid derivative essential for mitochondrial fatty acid transport. " "Valproic acid (valproate) causes carnitine depletion and inhibits mitochondrial β-oxidation, leading to hepatotoxicity " "and hyperammonemia. L-Carnitine supplementation specifically reverses this deficiency.", body_style)) story.append(Paragraph("Mechanism of Action Flowchart:", h3_style)) lc_fc = [ "VALPROIC ACID HEPATOTOXICITY", "Valproate → mitochondrial β-oxidation inhibition → carnitine depletion", "↓", "Toxic acylcarnitine accumulation", "↓", "Mitochondrial dysfunction → hyperammonemia", "↓", "L-CARNITINE SUPPLEMENTATION", "↓", "Restores carnitine pool", "↓", "Restores mitochondrial fatty acid transport", "↓ ↓", "↓ Toxic ↓ Ammonia levels", "acylcarnitine", "↓", "HEPATOCYTE PROTECTION + RECOVERY FROM HYPERAMMONEMIA", ] for line in lc_fc: story.append(Paragraph(line, code_style)) lc_data = [ ['Parameter', 'Details'], ['Indications', 'Valproate-induced hepatotoxicity with hyperammonemia (primarily children)\nValproate-induced encephalopathy'], ['Dose', 'Acute IV: 100 mg/kg/day (max 3 g/day) in hyperammonemic emergency\nMaintenance oral: 50–100 mg/kg/day in divided doses'], ['Contraindications', 'Known hypersensitivity to L-carnitine\nCaution in seizure disorders (seizures reported rarely)'], ['ADRs', 'Nausea, vomiting, diarrhea (oral route)\nFishy body odor (due to trimethylamine metabolite)\nSeizures reported (rare)'], ['Drug Interactions', 'Valproic acid: therapeutic reversal of depletion\nAcenocoumarol/warfarin: may enhance anticoagulant effect (monitor INR)'], ] story.append(tbl(lc_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 6: LACTULOSE ─────────── story.append(Paragraph("DRUG 6: LACTULOSE (for Hepatic Encephalopathy in DILI/ALF)", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Osmotic Laxative; Ammonia-Lowering Agent", body_style)) lac_fc = [ "HEPATIC ENCEPHALOPATHY (complication of DILI/ALF)", "Ammonia (NH3) levels elevated → crosses BBB → encephalopathy", "↓", "LACTULOSE (non-absorbable disaccharide — oral/enema)", "↓", "Colonic bacterial fermentation → Lactic acid + Acetic acid", "↓", "COLON ACIDIFICATION (pH ↓ to ~5)", "↓", "NH3 → NH4+ (trapped, non-absorbable ion)", "↓ ↓", "OSMOTIC Ammonia excreted in feces", "LAXATIVE ↓ Serum ammonia", "EFFECT ↓", "↓ IMPROVEMENT IN HE GRADE", "(2-3 soft stools/day is target)", ] for line in lac_fc: story.append(Paragraph(line, code_style)) lac_data = [ ['Parameter', 'Details'], ['Indications', 'Hepatic encephalopathy (HE) complicating DILI-induced ALF or cirrhosis\nFirst-line treatment for HE Grade I-III'], ['Dose', 'Oral: 15–30 mL (10–20 g) 2–4× daily; titrate to 2–3 soft stools/day\nRectal enema: 300 mL lactulose + 700 mL water for acute severe HE'], ['Contraindications', 'Galactosaemia (contains lactose/galactose)\nBowel obstruction\nDiabetes mellitus (relative — monitor glucose)'], ['ADRs', 'Bloating, flatulence, cramping, diarrhea (dose-limiting)\nHypernatremia (dehydration with excessive diarrhea)\nAspiration risk if encephalopathic patient given orally'], ['Drug Interactions', 'Antacids: may reduce lactulose acidification effect\nNeomycin/Rifaximin: additive ammonia-lowering effect (synergistic combination)'], ] story.append(tbl(lac_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ─────────── DRUG 7: Rifaximin ─────────── story.append(Paragraph("DRUG 7: RIFAXIMIN (for Hepatic Encephalopathy)", drug_header_style)) story.append(Spacer(1, 4)) story.append(Paragraph("<b>Class:</b> Non-Systemic (Non-Absorbable) Antibiotic; Rifamycin Derivative", body_style)) story.append(Paragraph( "<b>Introduction:</b> Rifaximin acts locally in the GI tract to reduce urease-producing bacteria, thereby lowering ammonia " "production and absorption. Used as an adjunct or alternative to lactulose for HE in DILI/ALF.", body_style)) rif_data = [ ['Parameter', 'Details'], ['Dose', '550 mg orally twice daily (BID)'], ['Indications', 'Hepatic encephalopathy (HE) — adjunct or alternative to lactulose\nSecondary prevention of overt HE episodes'], ['Contraindications', 'Bowel obstruction; known hypersensitivity to rifaximin or rifamycins'], ['ADRs', 'Nausea, abdominal pain (mild, due to low systemic absorption)\nDiarrhea (rare)\nPeripheral edema (rare)'], ['Drug Interactions', 'Minimal due to low systemic absorption (<0.4%)\nWarfarin: may slightly alter INR (monitor)\nP-glycoprotein substrates: rifaximin may inhibit P-gp locally'], ] story.append(tbl(rif_data, [4.5*cm, PAGE_W-4.5*cm])) story.append(Spacer(1, 0.4*cm)) # ============================================================ # 10. PHARMACOLOGICAL TREATMENT SUMMARY CHART # ============================================================ story.append(PageBreak()) story.append(Paragraph("10. PHARMACOLOGICAL TREATMENT — SUMMARY CHART", h1_style)) story.append(Spacer(1, 3)) summary_data = [ ['Drug', 'Class', 'MOA (Brief)', 'Indication in DILI', 'Dose', 'Key ADRs', 'Contraindications', 'Key Interaction'], ['N-Acetylcysteine\n(NAC)', 'Antidote /\nGSH precursor', 'Replenishes\nglutathione;\ndetoxifies NAPQI;\nreduces ROS', 'APAP overdose;\nnon-APAP ALF;\nsevere DILI', 'IV: 150→50→100\nmg/kg (3-bag);\nOral: 140 mg/kg\nload then 70\nmg/kg q4h ×17', 'IV: anaphylactoid\nreaction (rare);\nnausea/vomiting\n(oral)', 'NAC allergy;\ncaution severe\nasthma\n(inhalation)', 'Activated charcoal\n→ ↓ absorption;\nseparate doses'], ['Ursodeoxycholic\nAcid (UDCA)', 'Cytoprotective\nbile acid', 'Displaces toxic\nbile acids;\nstabilizes\nmembranes;\ncholeretic;\nimmuno-\nmodulatory', 'Cholestatic DILI;\npruritus;\ncholestasis\nrecovery', '13–15 mg/kg/day\nPO in 2–4\ndivided doses;\ncontinue until\nresolution', 'Diarrhea;\nnausea;\ntransient pruritus\n(initial)', 'Complete biliary\nobstruction;\nacute\ncholecystitis', 'Cholestyramine/\nantacids → ↓\nUDCA absorption\n(separate 2 hr)'], ['Prednisolone /\nMethyl-\nprednisolone', 'Glucocorticoid\n(Immunosuppres-\nsant)', 'Binds GCR;\ninhibits NF-κB;\n↓ TNF-α, IL-1β,\nIL-6; suppresses\nT-cells', 'Hypersensitivity\nDILI; DRESS;\ncheckpoint\ninhibitor hepatitis;\nautoimmune-\nfeatured DILI', 'Pred: 0.5–2\nmg/kg/day PO;\nMethylpred:\n1–2 mg/kg/day\nIV; gradual taper', 'Hyperglycemia;\ninfection;\nGI bleed;\nosteoporosis;\nHPA suppression', 'Active untreated\ninfection;\nnon-immune DILI;\nuncontrolled DM', 'NSAIDs: ↑ GI\nbleed; rifampicin:\n↓ steroid levels;\nazoles: ↑ steroid\nlevels'], ['Cholestyramine', 'Bile acid\nsequestrant\n(anion exchange\nresin)', 'Binds bile acids\nin GI lumen;\ninterrupts\nenterohepatic\ncirculation', 'Pruritus\n(cholestatic DILI);\nleflunomide\nhepato-toxicity\nwashout', '4 g 2–4×/day;\nLeflunomide:\n8 g TID × 11\ndays', 'Constipation;\nbloating;\nfat-soluble\nvitamin\ndeficiency', 'Complete biliary\nobstruction;\nbowel\nobstruction', 'Binds ALL drugs\n→ give other\ndrugs 1 hr before\nor 4–6 hr after'], ['L-Carnitine', 'Metabolic\ncofactor /\namino acid\nderivative', 'Restores\nmitochondrial\nfatty acid\ntransport; ↓\nacylcarnitine;\n↓ NH3', 'Valproate\nhepatotoxicity +\nhyperammonemia\n(especially\nchildren)', 'IV: 100 mg/kg/d\n(max 3g); Oral:\n50–100 mg/kg/d\nin divided doses', 'Nausea, fishy\nodor, diarrhea\n(oral); seizures\n(rare)', 'Hypersensitivity\nto L-carnitine', 'Valproate:\ntherapeutic\nreversal;\nwarfarin: monitor\nINR'], ['Lactulose', 'Osmotic\nlaxative /\nAmmonia-\nlowering agent', 'Acidifies colon;\ntraps NH4+;\nosmotic\ncatharsis; ↓\nserum ammonia', 'Hepatic\nencephalopathy\n(HE) complicating\nDILI/ALF', 'Oral: 15–30 mL\n2–4×/day; target\n2–3 soft\nstools/day;\nRectal enema for\nacute severe HE', 'Bloating,\nflatulence,\ncramping,\ndiarrhea', 'Galactosaemia;\nbowel\nobstruction', 'Antacids: ↓\nacidification;\nrifaximin: additive\n(synergistic)'], ['Rifaximin', 'Non-absorbable\nantibiotic\n(rifamycin)', '↓ Urease-\nproducing gut\nbacteria → ↓\nNH3 production\nand absorption', 'Hepatic\nencephalopathy\n(adjunct or\nalternative\nto lactulose)', '550 mg PO\nBID', 'Nausea, abdominal\npain (mild,\nminimal systemic\nabsorption)', 'Bowel\nobstruction;\nrifamycin\nallergy', 'Minimal (low\nSA); warfarin:\nmonitor INR'], ['Diphenhydramine\n/ Hydroxyzine', 'Antihistamine\n(H1 blocker)', 'Blocks H1\nreceptors;\nsedation;\n↓ itch\nperception', 'Symptomatic\npruritus in DILI', 'Diphenhydra-\nmine: 25–50 mg\nPO/IV q4–6h\nPRN; Hydroxy-\nzine: 25 mg\nq6–8h PO', 'Sedation,\nanticholinergic\neffects (dry\nmouth, urinary\nretention,\nconstipation)', 'Closed-angle\nglaucoma; BPH;\ncaution HE\n(sedation risk)', 'CNS depressants:\nadditive sedation'], ] # wider summary table sum_t = Table(summary_data, colWidths=[2.5*cm, 2.3*cm, 2.5*cm, 2.8*cm, 2.8*cm, 2.4*cm, 2.3*cm, 2.4*cm], repeatRows=1) sum_t.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#0d47a1')), ('TEXTCOLOR', (0,0), (-1,0), colors.white), ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'), ('FONTSIZE', (0,0), (-1,0), 7.5), ('ALIGN', (0,0), (-1,-1), 'LEFT'), ('VALIGN', (0,0), (-1,-1), 'TOP'), ('FONTNAME', (0,1), (-1,-1), 'Helvetica'), ('FONTSIZE', (0,1), (-1,-1), 7), ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.white, colors.HexColor('#e8f4f8')]), ('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#b0bec5')), ('TOPPADDING', (0,0), (-1,-1), 3), ('BOTTOMPADDING', (0,0), (-1,-1), 3), ('LEFTPADDING', (0,0), (-1,-1), 3), ('RIGHTPADDING', (0,0), (-1,-1), 3), ])) story.append(sum_t) story.append(Spacer(1, 0.4*cm)) # ============================================================ # 11. DRUG INTERACTIONS TABLE # ============================================================ story.append(PageBreak()) story.append(Paragraph("11. DRUG INTERACTIONS SUMMARY", h1_style)) story.append(Spacer(1, 3)) di_data = [ ['Object Drug', 'Precipitant Drug', 'Mechanism/Effect', 'Management'], ['Oral NAC', 'Activated charcoal', 'Charcoal adsorbs NAC in GI tract → ↓ absorption', 'Prefer IV NAC; if oral, separate by ≥1 hour'], ['NAC (IV)', 'Nitroglycerin', 'Additive vasodilation → hypotension', 'Monitor BP; reduce nitroglycerin dose if needed'], ['UDCA', 'Cholestyramine', 'Cholestyramine binds UDCA → ↓ absorption', 'Separate by 2 hours (UDCA before cholestyramine)'], ['UDCA', 'Al/Mg antacids', 'Antacids bind UDCA → ↓ absorption', 'Separate by 2 hours'], ['Cyclosporine', 'UDCA', 'UDCA increases cyclosporine absorption', 'Monitor cyclosporine blood levels'], ['Prednisolone', 'Rifampicin', 'Rifampicin induces CYP3A4 → ↑ steroid metabolism → ↓ steroid levels', 'Increase corticosteroid dose; monitor efficacy'], ['Prednisolone', 'Azole antifungals, Macrolides', 'CYP3A4 inhibition → ↑ steroid blood levels', 'Reduce steroid dose; monitor for steroid ADRs'], ['Prednisolone', 'NSAIDs', 'Additive prostaglandin inhibition → ↑ GI bleeding risk', 'Avoid combination; add PPI prophylaxis'], ['Antidiabetics', 'Prednisolone', 'Corticosteroid-induced hyperglycemia reduces hypoglycemic effect', 'Monitor blood glucose; adjust antidiabetic dose'], ['Live vaccines', 'Prednisolone', 'Immunosuppression → risk of vaccine-related infection', 'Avoid live vaccines during corticosteroid therapy'], ['Warfarin', 'Cholestyramine', 'Cholestyramine binds warfarin → ↓ absorption', 'Give warfarin 1 hr before cholestyramine; monitor INR'], ['Most drugs (general)', 'Cholestyramine', 'Anion exchange resin binds drugs non-specifically', 'RULE: Give all other drugs 1 hr before or 4–6 hr after cholestyramine'], ['Warfarin', 'L-Carnitine', 'May enhance anticoagulant effect', 'Monitor INR closely'], ['Lactulose', 'Antacids', 'Antacids may raise colonic pH → reduce lactulose acidification', 'Avoid concurrent use; monitor HE response'], ['Ammonia-lowering', 'Lactulose + Rifaximin', 'Synergistic reduction of ammonia (complementary mechanisms)', 'Effective combination for refractory HE'], ] story.append(tbl(di_data, [3.5*cm, 3.5*cm, 5.5*cm, PAGE_W-12.5*cm])) story.append(Spacer(1, 0.4*cm)) # ============================================================ # 12. SPECIAL CONSIDERATIONS # ============================================================ story.append(Paragraph("12. SPECIAL CONSIDERATIONS", h1_style)) story.append(Spacer(1, 3)) story.append(Paragraph("12.1 Hy's Law", h2_style)) story.append(Paragraph( '<b>Definition:</b> ALT > 3× ULN + Total Bilirubin > 2× ULN (in absence of biliary obstruction / cholestasis) → ' 'approximately <b>10% mortality</b>. This is a critical prognostic marker — patients meeting Hy\'s Law criteria ' 'require urgent hepatology referral, escalation of care, and consideration of liver transplant evaluation.', note_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("12.2 King's College Criteria for Liver Transplant (ALF)", h2_style)) kcc_data = [ ['Criterion', 'Details'], ['Paracetamol-induced ALF', 'pH <7.3 after resuscitation, OR all 3 of: PT >100s + creatinine >300 µmol/L + Grade III-IV HE'], ['Non-paracetamol ALF', 'PT >100s, OR any 3 of: Age <10 or >40 yr; etiology: drug, NANBH; jaundice→HE >7 days; PT >50s; bilirubin >300 µmol/L'], ] story.append(tbl(kcc_data, [5*cm, PAGE_W-5*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("12.3 Chronic DILI", h2_style)) story.append(Paragraph( 'Acute DILI progresses to chronic liver injury in 5–10% of cases. ' '<b>Chronic DILI</b> is defined as persistence of liver injury >3 months after stopping the drug. ' 'Histologic patterns include: chronic hepatitis, cirrhosis, vanishing bile duct syndrome (ductopenia), ' 'steatosis, and progressive hepatic fibrosis. Management follows chronic liver disease protocols.', body_style)) # ============================================================ # 13. QUICK SUMMARY TABLE # ============================================================ story.append(PageBreak()) story.append(Paragraph("13. QUICK REVISION SUMMARY", h1_style)) story.append(Spacer(1, 3)) qs_data = [ ['Feature', 'Key Point'], ['Definition', 'Liver injury by drugs/xenobiotics; ALT >3× or ALP >2× ULN; diagnosis of exclusion'], ['Types', 'Intrinsic (dose-dependent, predictable) | Idiosyncratic (unpredictable) | Indirect (immune-mediated)'], ['Most common cause', 'Acetaminophen (intrinsic); Amoxicillin-clavulanate (idiosyncratic, Western)'], ['Most common cause of ALF', 'Acetaminophen — responsible for ~50% of ALF in USA'], ['R Ratio formula', '(ALT/ULN) ÷ (ALP/ULN) → >5: hepatocellular; <2: cholestatic; 2–5: mixed'], ["Hy's Law", 'ALT >3× ULN + Bilirubin >2× ULN = ~10% mortality → urgent evaluation'], ['Causality assessment', 'RUCAM (Roussel Uclaf Causality Assessment Method) — standard tool; >8 = highly probable'], ['FIRST treatment step', 'STOP the offending drug immediately (most important step)'], ['Antidote for APAP toxicity', 'N-Acetylcysteine (NAC) — IV preferred; IV 3-bag regimen or oral 72-hour regimen'], ['Cholestatic pruritus', 'Ursodeoxycholic acid (UDCA) + Cholestyramine'], ['Immune/hypersensitivity DILI', 'Corticosteroids (Prednisolone 0.5–2 mg/kg/day, taper)'], ['DRESS syndrome', 'Prednisolone 1–2 mg/kg/day; continue until resolution then slow taper'], ['Checkpoint inhibitor hepatitis', 'Methylprednisolone 1–2 mg/kg/day IV (Grade 3–4)'], ['Valproate hepatotoxicity', 'L-Carnitine IV + Stop valproate'], ['Hepatic encephalopathy', 'Lactulose (target 2–3 stools/day) ± Rifaximin (550 mg BID)'], ['Leflunomide toxicity washout', 'Cholestyramine 8 g TID × 11 days'], ['ALF — when to transplant', "King's College criteria; transfer to transplant center early"], ['Chronic DILI definition', 'Liver injury persisting >3 months after drug discontinuation (5–10% of cases)'], ['Pharmacist role', 'Identify hepatotoxic drugs, monitor LFTs, counsel patients, report ADRs, avoid re-exposure'], ] story.append(tbl(qs_data, [5.5*cm, PAGE_W-5.5*cm])) story.append(Spacer(1, 0.4*cm)) # References story.append(Paragraph("References", h2_style)) refs = [ "Goldman-Cecil Medicine, International Edition — Chapter 136: Drug-Induced Liver Injury", "Washington Manual of Medical Therapeutics (9781975190620)", "Yamada's Textbook of Gastroenterology, 7th Edition — Chapter 89", "Robbins & Cotran Pathologic Basis of Disease (9780443264528)", "Goodman & Gilman's Pharmacological Basis of Therapeutics", "Harrison's Principles of Internal Medicine, 22E", "Lippincott's Illustrated Reviews: Pharmacology", "PharmdGuru.com — Drug Induced Liver Disorders", "Ozturk et al. (2025). Hepatology Forum. PMID: 40248678", "Hosack et al. (2023). Ther Adv Gastroenterol. PMID: 36968618", "Kozielewicz et al. (2025). Clin Exp Hepatol. PMID: 40303582", "AASLD Practice Guidance on DILI (2023); EASL Clinical Practice Guidelines: DILI (2019)", ] for r in refs: story.append(Paragraph(f"• {r}", bullet_style)) story.append(Spacer(1, 0.3*cm)) story.append(HRFlowable(width="100%", thickness=1, color=colors.HexColor('#1a237e'))) story.append(Paragraph("Therapeutics 3 — Drug-Induced Liver Disorders | Compiled: August 2026", ParagraphStyle('footer', parent=styles['Normal'], fontSize=8, textColor=colors.gray, alignment=TA_CENTER))) # Build doc.build(story) print("PDF created successfully!") EOF
Drug Induced Liver Disorders Therapeutics3
PDF Document · PDF
Drug Induced Liver Disorders Therapeutics3
MD File · MD
What's Included (Full Structure)
1. Introduction
- DILI = ~50% of all ALF in USA; acetaminophen is the most common single cause
-
1,000 drugs implicated (NIH LiverTox database)
2. Definition
- Biochemical thresholds: ALT/AST >3× ULN, ALP >2× ULN, Bilirubin >2× ULN
- R Ratio = (ALT/ULN) ÷ (ALP/ULN): >5 hepatocellular | <2 cholestatic | 2-5 mixed
3. Etiology
- Table covering 11 drug classes with examples and injury type (analgesics, antitubercular, antibiotics, anticonvulsants, antifungals, cardiovascular, immunosuppressants, herbal, checkpoint inhibitors, etc.)
4. Pathophysiology (Flowchart)
- Step-by-step ASCII flowcharts for intrinsic vs. idiosyncratic mechanisms
- Key mechanisms table: CYP450 toxic metabolite, mitochondrial dysfunction, hapten formation, BSEP inhibition, HLA-restricted immune activation
5. Clinical Features
- General, hepatic-specific, severe/ALF, and DRESS syndrome features
6. Diagnosis
- Full diagnostic algorithm; RUCAM scoring table; Hy's Law
- First-line and second-line investigation tables with R ratio classification
7. Treatment Goals (Priority table 1-7)
8. Non-Pharmacological Treatment
- 11-point table including drug withdrawal, GI decontamination, nutritional support, hospitalization criteria, transplant evaluation
9. Pharmacological Treatment — 7 Detailed Drug Profiles
| Drug | Class | Key Indication |
|---|---|---|
| N-Acetylcysteine | Antidote/GSH precursor | Paracetamol overdose; non-APAP ALF |
| UDCA (Ursodiol) | Cytoprotective bile acid | Cholestatic DILI; pruritus |
| Prednisolone/Methylprednisolone | Glucocorticoid | Hypersensitivity DILI; DRESS; checkpoint inhibitor hepatitis |
| Cholestyramine | Bile acid sequestrant | Pruritus; leflunomide washout |
| L-Carnitine | Metabolic cofactor | Valproate hepatotoxicity + hyperammonemia |
| Lactulose | Osmotic laxative | Hepatic encephalopathy in DILI/ALF |
| Rifaximin | Non-absorbable antibiotic | Hepatic encephalopathy (adjunct) |